한글목차

본 보고서는 2025년 3분기 신흥 시장 의약품 제조 환경을 종합적으로 조사하고, CMO에 영향을 미치는 뉴스 및 동향 분석과 함께 CMO의 최근 위탁 서비스 계약, 합병, 인수, 자금 조달에 대한 정보를 제공합니다.

목차

• 산업 동향
• 토글 메뉴
• 인도 제약사들, CDSCO가 부과한 신규 제조 규정 비판
• 중국 제11차 중앙집중 조달 프로그램, 입찰 및 가격 책정 개선으로 과도한 저가 경쟁 완화하며 이정표 마련
• 산업 분석
• 토글 메뉴
• 신흥 시장 수탁 서비스 계약
• 신흥 시장 분기별 합병, 인수, 자금조달 - 2025년 3분기
• 밸류체인
• 토글 메뉴
• API 화학제품
• API 생물학적 제제 - 단백질, 펩티드
• API 생물학적 제제(세포, 유전자, 백신, 바이러스 요법)
• 임상 용량 제조와 포장
• 상업 용량 제조와 포장
• 애널리틱스 서비스
• 규제 발전
• 저자에 대해
• GlobalData에 대해
• 문의

영문목차

This expert outsourcing report is a comprehensive look at the pharmaceutical manufacturing landscape for emerging markets in Q3 2025, including analysis of news and trends affecting contract manufacturing organizations (CMOs) and the identification of recent contract service agreements, mergers, acquisitions, and financing among CMOs. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the pharmaceutical value chain that will provide insights into API (biologics and chemical) as well as dose manufacturing and packaging (clinical and commercial) for countries in emerging markets.

Scope

This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from GlobalData's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for -

• CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
• Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
• Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.

Reasons to Buy

This report will enable the user to answer the following questions -

• What are the latest trends in contract service agreements within the emerging markets of the pharmaceutical industry such as India, China, the Middle East, South America, and Eastern Europe?
• What mergers and acquisitions have occurred in the pharmaceutical sector during Q2 2025, and what do they signify for the industry?
• How are global supply chains for active pharmaceutical ingredients (APIs) being affected by regulatory changes and inspections?
• What are the key challenges and opportunities for contract research, development, and manufacturing organizations (CRDMOs)?
• What are the outcomes of FDA inspections and compliance issues for pharmaceutical manufacturers?

Table of Contents

Table of Contents

• Industry Trends
• Toggle menu
• Pharmaceutical firms in India criticize new manufacturing regulations imposed by the CDSCO
• China's 11th Centralized Procurement Program marks milestone with improved bidding, price setting to ease excessive low-price competition
• Industry Analysis
• Toggle menu
• Emerging market contract service agreements
• Emerging market quarterly mergers, acquisitions, and financing - Q3 2025
• Value Chain
• Toggle menu
• API chemical
• API biologics - protein and peptide
• API biologics (cell, gene, vaccine, and virus therapies)
• Clinical dose manufacturing and packaging
• Commercial dose manufacturing and packaging
• Analytical services
• Regulatory developments
• About the Authors
• About GlobalData
• Contact Us